Stocktoria
Enliven Therapeutics, Inc. ELVN
Enliven Therapeutics, Inc. (ELVN) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-01 | Stifel | Buy (main) |
| 2026-06-29 | Jones Trading | Buy (main) |
| 2026-06-09 | Stifel | Buy (init) |
| 2026-06-02 | Mizuho | Outperform (main) |
| 2026-05-08 | Goldman Sachs | Buy (main) |
| 2026-03-26 | HC Wainwright & Co. | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | 3/9 | — | — | — |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
FAQ
Is ELVN financially healthy?
Enliven Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does ELVN pay a dividend?
No, Enliven Therapeutics, Inc. does not currently pay a dividend.
How profitable is ELVN?
In FY2025, Enliven Therapeutics, Inc. had a return on equity of -22.6%.
What is the analyst price target for ELVN?
The average Wall-Street price target for Enliven Therapeutics, Inc. is $65.11, about 12.4% above the recent price, from 9 analysts (consensus: strong buy).
Is ELVN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Enliven Therapeutics, Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.